20 3月 2020 by admin in UncategorizedComments Design Therapeutics Launches with $45 Million to Develop a New Class of Disease-Modifying Therapies for Serious Degenerative Disorders
12 3月 2020 by admin in UncategorizedComments resTORbio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
12 3月 2020 by admin in UncategorizedComments NextCure Reports Fourth Quarter and Full Year 2019 Financial Results
12 3月 2020 by admin in UncategorizedComments Arcellx Announces FDA Orphan Drug Designation for CART-ddBCMA for the Treatment of Multiple Myeloma
28 2月 2020 by admin in UncategorizedComments Arcellx Announces First Patient Treated with T Cell Therapy Utilizing the Company’s Novel Binding Domain
30 1月 2020 by admin in UncategorizedComments TEMPEST THERAPEUTICS ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR TPST-1495 AND WELCOMES NEW INVESTORS
20 12月 2019 by admin in UncategorizedComments Syros Announces Appointment of Mark Alles to Its Board of Directors
18 12月 2019 by admin in UncategorizedComments GBT and Syros Partner to Discover, Develop and Commercialize Novel Therapies for Sickle Cell Disease and Beta Thalassemia
03 12月 2019 by admin in UncategorizedComments Centrexion Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Lead Pipeline Candidate CNTX-4975
